Alps Advisors Inc. raised its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 5.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 146,867 shares of the biopharmaceutical company’s stock after buying an additional 8,136 shares during the period. Alps Advisors Inc. owned 0.09% of Horizon Pharma PLC worth $1,743,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of HZNP. Bank of Montreal Can boosted its position in shares of Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 1,378 shares during the period. Sheaff Brock Investment Advisors LLC acquired a new position in shares of Horizon Pharma PLC during the first quarter valued at about $148,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Horizon Pharma PLC during the first quarter valued at about $151,000. Teacher Retirement System of Texas boosted its position in shares of Horizon Pharma PLC by 12.8% in the second quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 1,466 shares during the period. Finally, Stevens Capital Management LP acquired a new position in shares of Horizon Pharma PLC during the first quarter valued at about $173,000. 83.75% of the stock is owned by hedge funds and other institutional investors.

Shares of Horizon Pharma PLC (HZNP) opened at 13.14 on Friday. The stock has a 50 day moving average of $12.50 and a 200 day moving average of $13.54. The firm’s market cap is $2.15 billion. Horizon Pharma PLC has a 12 month low of $9.45 and a 12 month high of $23.24.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.29. The business had revenue of $289.51 million during the quarter, compared to the consensus estimate of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The business’s revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.56 EPS. On average, equities research analysts expect that Horizon Pharma PLC will post $1.07 EPS for the current fiscal year.

Horizon Pharma PLC declared that its Board of Directors has initiated a share buyback plan on Monday, May 8th that authorizes the company to repurchase 1,000% of shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/18/alps-advisors-inc-acquires-8136-shares-of-horizon-pharma-plc-hznp.html.

HZNP has been the subject of several recent research reports. Citigroup Inc. reduced their target price on shares of Horizon Pharma PLC from $20.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, May 9th. Jefferies Group LLC set a $14.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Tuesday, May 9th. Stifel Nicolaus reissued a “buy” rating and set a $20.00 target price (down previously from $35.00) on shares of Horizon Pharma PLC in a report on Tuesday, May 9th. BMO Capital Markets reissued a “buy” rating and set a $17.00 target price (down previously from $24.00) on shares of Horizon Pharma PLC in a report on Tuesday, May 9th. Finally, UBS AG set a $16.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Wednesday, June 7th. Five investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Horizon Pharma PLC has an average rating of “Buy” and an average target price of $19.46.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Stock Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related stocks with our FREE daily email newsletter.